Product Images Terazosin

This text appears to be a chemical formula for the compound HCl with water, along with information about its molecular weight. However, it is not a complete or coherent sentence, and more contextual information would be needed to provide a more useful description.*

The text contains results of three studies evaluating the impact of Terazosin on patients' symptom score and peak flow rate. The studies had varying dosages and durations for titration to response and fixed dosages. The results indicate that Terazosin had a significant positive impact on symptom score and peak flow rate compared to the placebo in all studies, with some dosages showing higher improvement rates than others. There is also information about the number of patients who responded positively to the highest dosages, with 41% showing improvement on 20mg and 67% on 10mg.*

This text describes a figure presenting the results of a study on the effectiveness of terazosin for treating symptoms related to a specific condition. The figure shows the mean change in total symptom score and mean increase in peak flow rate over the course of three months for a group given terazosin and a group given a placebo. The numbers in the table indicate the sample size for each group. The results indicate a significant improvement in both symptom score and peak flow rate for the terazosin group compared to the placebo group.*

This is a graph that shows the Mean Change in Total Symptom Score from Baseline over a Long-Term, Open-Label, Non-Placebo Controlled Study that involved 494 participants. The graph shows the Mean Change from Baseline for each month up to 30 months. The asterisk denotes statistical significance.*

This is a graph showing the mean change in peak flow rate from baseline in a long-term, open-label, and non-placebo controlled study with a sample size of 494. The graph plots the mean change in milliliters per second (mL/sec) against time in months for a period of 30 months. The baseline mean is 9.9, and there is a statistically significant improvement (p<0.05) in peak flow rate from baseline.*

The text provides data on changes in Blood Pressure from baseline to the final visit in double-blind placebo-controlled studies. The data stratifies patients into Normotensive and Hypertensive patients based on their diastolic blood pressure (DBP) level. The data indicates the number of patients in each group, followed by the mean changes in their SBP (Systolic Blood Pressure) and DBP levels. The study compares the results for patients treated with Terazosin to those given a placebo. The study indicates a statistically significant reduction (p<0.05) in blood pressure levels for patients treated with Terazosin vs. Placebo.*

This is a table presenting adverse reactions during placebo-controlled trials for the treatment of Benign Prostatic Hyperplasia with the drug Terazosin compared to Placebo. The table lists the percentage of patients who experienced a range of adverse reactions, categorised by body system affected. The adverse reactions listed include Asthenia, Flu Syndrome, Headache, Hypotension, Palpitations, Postural Hypotension, Syncope, Nausea, Peripheral Edema, Weight Gain, Dizziness, Somnolence, Vertigo, Dyspnea, Nasal Congestion/Rhinitis, Blurred Vision/Amblyopia, Impotence, and Urinary Tract Infection. The table suggests that Terazosin had a higher incidence of Asthenia, Postural Hypotension and Dizziness and was more effective in reducing urinary tract infections compared to Placebo.*

This table displays the rates of discontinuation during placebo-controlled trials for benign prostatic hyperplasia. It provides percentages for the different symptoms experienced under the various body systems such as body as a whole, cardiovascular system, digestive system, nervous system, respiratory system and urogenital system. The symptoms reported are fever, headache, postural hypotension, syncope, nausea, dizziness, vertigo, dyspnea, blurred vision/amblyopia and urinary tract infection.*

This is a table showing the adverse reactions reported during placebo-controlled trials of terazosin. The table has different body systems, such as cardiovascular, nervous, and respiratory systems, and shows the percentage of participants who reported adverse reactions for terazosin and placebo. Some adverse reactions were statistically significant for terazosin at a p = 0.05 level. Adverse reactions reported include asthenia, back pain, headache, palpitations, postural hypotension, nausea, edema, weight gain, depression, dizziness, libido decreased, dyspnea, nasal congestion, sinusitis, blurred vision, and impotence.*

This is a table showing the percentage of patients who discontinued use of terazosin and placebo during hypertension trials due to various side effects. Some of the side effects include asthenia, headache, palpitations, postural hypotension, syncope, tachycardia, nausea, peripheral edema, dizziness, paresthesia, somnolence, dyspnea, nasal congestion, and blurred vision.*

Terazosin is a medication that comes in a capsule form and has a quantity of 30. The lot number is missing and it is manufactured by Avet Pharmaceuticals Inc. It should be stored between 20-26°C (63-77°F), with excursion permitted to 15-30°C (59-86°F) and is available only with a prescription. The packaging has been done by RemedyRepack Inc. Children should be kept away from this medication. For instructions on how to use this medicine, kindly refer to the package insert.*